Shot-hole borer researchers team up against tree-killing beetle in Perth
In addition, since 2021 the city has been struggling to contain a tree-killing invasive beetle — the polyphagous shot-hole borer.
The pest, which produces a deadly fungus, mainly infects exotic trees, but native varieties like melaleucas are also at risk.
To quell the spread of the beetle, the state government has to date removed 4,794 trees, some from Perth's most popular green spaces — Kings Park, Hyde Park and Stirling Gardens.
Last month, a national biosecurity taskforce moved from an eradication response to long-term management, worrying many working in the space, particularly those in WA's agriculture sector.
Teams of researchers are working on new methods to identify, contain and kill the beetle.
Funded by the WA government through the WA Agriculture Research Centre (WAARC), three major projects have received $2.17 million, paying for three years of research.
Key stakeholders met this week at a symposium to hear from the funding recipients about their research so far.
Theo Evans, associate professor of applied entomology at the University of Western Australia, told the symposium two trials, which commenced in September 2024, showed very promising early results.
He has been trialling two methods to combat the borer — a chemical injection into infected trees and using commercially available nematodes to eat the beetle.
Treena Burgess, forest pathologist and director of the Harry Butler Institute, has been overseeing several studies at Murdoch University, most notably one into the fungus the beetle produces.
"A key piece of our research is going to be trying to understand how susceptible different tree species are to the fungus," Professor Burgess said.
"The beetle is the vector, and the fungus is the killer of trees, and different tree species seem to be varying considerably in their susceptibility."
She said some trees responded better than others to the infection.
Professor Burgess said the need for information on the beetle was so acute that the universities and stakeholders would share data as it came to hand, rather than waiting for the lengthy peer-review process.
"The purpose of this is to solve the problem," she said.
Managing director of environmental consultancy ArborCarbon and adjunct professor at Murdoch University Paul Barber will use funding to send up an "ArborCam" to map Perth's tree coverage.
ArborCarbon has already led biosecurity responses in the eastern states.
"The ArborCam is special because it can collect 11 bands of data across the spectrum, and it measures things like the condition of vegetation, height, surface temperatures," Professor Barber said.
ArborCarbon will use the technology to identify where the most susceptible trees are, to focus on-the-ground efforts.
Professor Barber said the goal was to make the ArborCam data available online for stakeholders and researchers.
Ben Phillips, professor of population biology at Curtin University, is creating models to understand how the shot-hole borer might spread, and measure how effective current methods of detection are.
He has taken information from dozens of studies to create a model of population growth, and his team has discovered population growth is dependent on temperature.
"Most of the eastern seaboard of Queensland is looking like a spot for the borer, particularly the area around Cairns."
He said considering Perth did not even have the ideal climate, the beetle had an incredibly high growth rate.
The female borer does not require a male to reproduce, and Professor Phillip's modelling showed the population could grow in Perth conditions from one to a million in just a year.
All the researchers the ABC spoke to were optimistic their efforts would lead to better management tools for the dreaded pest.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
44 minutes ago
- News.com.au
Health Check: Cancer drug developers drive further positive Car-T results
Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow There's a long drive ahead, but Imugene (ASX:IMU) and Chimeric Therapeutics (ASX:CHM) are heading in the right direction with their Car-T therapies that trick up the body's T-cells to be better cancer fighters. Imugene shares this morning leaped 10%, after the company reported two additional 'partial responses' in its phase 1b trial. The study aims to combat relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. Imugene's Car-T therapy, azer-cel, could result in the first 'off the shelf' Car-T treatment derived from donor cells (rather than the patient). The trial tally now stands at six 'complete responses' and five partial responses. A complete response is disappearance of signs of cancer – tentatively known as a cure. A partial response is a cancer reduction of at least 50%. In all, the trial has achieved an overall response rate of 79%. On July 14 Imugene said nine out of 12 patients had responded, prompting a circa $37 million capital raising. The first patients dosed (last year) remain cancer free at 15 months. They had not responded to several therapy attempts. The trial is underway at ten US sites and six local sites, including Sydney's Royal Prince Alfred Hospital. Cells are 'hard at work' Chimeric reports 'encouraging early results' after moving to a stronger dose in its phase I/II study. The trial tests the company's Car-T candidate CHM CDH17. Chimeric reports one patient with stable disease and "anti-tumour activity", with the lesion shrinking by 12%. The boffins define stable disease as no change in tumour size, or up to 30% shrinkage. One patient from the first dose cohort remains with stable disease eight months after dosing, with an 18% shrinkage. 'This is great progress,' says Chimeric CEO Dr Rebecca McQualter. 'We can see the cells are hard at work to more data'. The trial has enrolled patients with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours. CHM CDH17 targets CDH17, a cancer biomarker 'associated with poor prognosis and metastases in the most common gastrointestinal tumours'. Chimeric expects to enrol 15 patients in the phase I part of the study, with an expanded cohort for phase II. Rhythm's test validation is in the groove Rhythm Biosciences (ASX:RHY) shares today surged a sector-leading ing 18%, on further validation results of the company's Colostat bowel cancer assay. Having received its first kits from the manufacturer for final internal testing, the company tested them on new blood samples from patients with no bowel cancer at any of the stages (one to four). 'This study was critical as the initial intended use of Colostat is for symptomatic patients who could well have early and late-stage disease,' the company says. While Rhythm will complete further studies, the data on 300 patient samples shows that Colostat is equally effective at detecting bowel cancer across all stages. Rhythm will apply to the local National Association of Testing Authorities to have Colostat approved under the common-used laboratory-developed route. Lung imager breathes easier with deep-pocketed backer Friday's keen investor response to lung imager 4D Medical's 4D Medical's (ASX:4DX) funding arrangement with ProMedicus (ASX:PME) no doubt has to do with the mere 'vibe' of the latter taking an interest in the market minnow. In its first tie up with a listed peer, the $30 billion market cap Pro Medicus has extended a $10 million 'hybrid debt and equity loan' to 4D Medical. The duo don't compete with each other. 4D Medical will use the funds to develop its product pipeline and advance a US Food and Drug Administration (FDA) marketing application. This is for the company's ventilation perfusion product, for use in computed tomography. The loan attracts 12.5% interest and is repayable in cash and 'shares valued at the same amount as the cash repayment'. The deal is non-dilutive if the share price remains where is it, with 'upside alignment' for both parties if they perform strongly over the next two years. 4D also reported customer receipts of $1.61 million for the June quarter, up 19%, taking full-year receipts to $12 months to $5.38 million (up 87%). The company undertook 74,000 scans for the quarter, up 105% year on year. 4D had outflows of $9.47 million, down 16% compared with the March quarter. The company ended June with cash of $9.9 million, with a $6 million R&D tax refund due 'in coming weeks'. 4D Medical shares surged 30% on Friday and edged up a further 10% today. Spare us a dime? Other life companies are bringing in the dollars via traditional equity means. The developer of a non-radiation-based imaging for breast and other cancers, Imagion Biosystems (ASX:IBX) has raised $3.5 million in a two-tranche institutional placement. The price was 1.5 cents per share, a 10% discount. The funds will support Imagion's proposed phase II US trial for Her-2 breast cancers. Nyrada (ASX:NYR) has raised $8.25 million via a placement. The company is developing Xolatryp, which blocks a certain ion channel to protect key cells in vital organs when under stress. This could be after a blood clot or reperfusion (the sudden flow of blood returning to an organ or tissue). Nyrada is preparing for a phase IIa acute myocardial infarction trial and has nearly finished a phase I cardioprotection study. Kiwi diagnostics house Pacific Edge (ASX:PEB) has raised NZ$20.7 million in a placement and share purchase plan, having targeted NZ$20 million. US authorities recently cancelled reimbursement of the Pacific Edge's bladder cancer test Cxbladder, but the company is challenging the decision. Finally, foetal monitoring house HeraMED (ASX:HMD) has raised $1.98 million 1.2 cents a share, a 4.8% discount. Reporting latecomers: please wait to be seated Companies needed to lodge their quarterly reports within a month. But the ASX 'ushers' will still see them to their seats if they're not too late. The bourse on Friday suspended Syntara (ASX:SNT) for non-lodgment – but not for long. The myelofibrosis drug developer was allowed to resume trading, having lodged before the opening of Friday's trading. The quarterlies were due on Thursday. Syntara reported receipts of $78,000, cash outflow of $3.7 million and a $15 million cash balance. By the end of September, investors should expect final results from the company's phase II program that evaluated its drug candidate amsulostat, in 16 patients. An interim readout showed eight of 11 evaluable patients (73%) achieved a reduction of 50% or more in their myelofibrosis symptoms. Syntara awaits an FDA review of its application to start a follow-on phase II/III trial. Meanwhile, Syntara will seek shareholder approval to grant 4.769 million of incentive shares to CEO Gary Phillips, at nil consderation.

News.com.au
7 hours ago
- News.com.au
Hope grows as cannabis contender enters the Rett syndrome fight
Rett syndrome is rare but relentless Neuren struck biotech gold with Daybue Neurotech brings cannabis to the fight Rett syndrome is the kind of diagnosis that hits hard and lingers long. It affects around one in 10,000 girls, and typically appears after what seems like a normal start to life. Then comes the regression - loss of speech, hand skills, mobility - followed by the onset of seizures, bone fragility, gut issues, scoliosis and, often, a haunting silence that replaces early babble. It's caused by mutations in the MECP2 gene, which plays a crucial role in brain development. While it's classed as rare, the ripple effects through families are enormous. Sleep disturbances are common. Breathing irregularities, like breath-holding spells, can leave caregivers powerless. And while most girls survive into adulthood, it's with round-the-clock support and complex medical needs. AussieRett and InterRett studies Professor Helen Leonard, principal research fellow at the Kids Research Institute, has spent decades studying the condition. Leonard's long-running AussieRett and InterRett studies have helped establish how Rett symptoms evolve over time, and her team has also created global care guidelines for things like nutrition, scoliosis and bone health. 'Rett syndrome is an unusual condition in that it mainly affects girls who, following a period of apparent normal development, gradually show signs of regression," she told Stockhead. "Between the ages of 6 and 18 months they lose skills, particularly in relation to hand function and communication. 'As well as loss of hand function, these individuals develop unusual patterns of hand movements, such as hand-wringing or clapping known as stereotypies." Neuren's moonshot moment Until recently, there was no approved treatment for Rett, only a patchwork of management strategies and hope. That changed when ASX-listed Neuren Pharmaceuticals (ASX:NEU) struck gold with its drug trofinetide, now marketed as DAYBUE in the US. Approved by the FDA in March 2023, DAYBUE became the first and only drug for Rett syndrome, unlocking a commercial windfall for Neuren. Since 2019, Neuren's stock has surged over 1,200%, and the company now commands a $2 billion market cap. Thanks to a savvy licensing deal with Acadia Pharmaceuticals, Neuren pockets royalties and milestone payments with no royalty outgoings - every dollar drops to the bottom line. 'The FDA approval of trofinetide for Rett syndrome is very exciting, and represents the first ever treatment for the disorder,' said Leonard. For investors, it was a reminder that rare paediatric disorders, long overlooked, are now a serious biotech frontier. And that's where Neurotech (ASX:NTI) enters the frame, with a somewhat different approach. Cannabis steps into the ring Neurotech's lead therapy, NTI164, is a full-spectrum cannabis extract containing a cocktail of cannabinoids like CBDA, CBC and CBN. But it only contains 0.08% THC, meaning it's non-intoxicating and suitable for children. The company recently published results from its Phase I/II study in the Journal of Paediatrics and Child Health. This report shows the therapy was well tolerated and offered signs of clinical improvement across neurological, behavioural and functional domains. The drug's unique formulation is designed to reduce neuroinflammation, support synaptic function and modulate glial cells - factors believed to play a key role in Rett's progression. NTI164 is gaining traction internationally. It's already secured Orphan Drug Designation (ODD) in the US and European Union. This unlocks a range of incentives, including market exclusivity, reduced regulatory fees and access to research funding. It's the kind of support that can help fast-track rare-disease drugs through the system. Meanwhile, data from the same study was presented by lead investigator Professor Carolyn Ellaway at the World Rett Syndrome Congress. That put NTI164 front and centre in a growing global conversation about next-gen Rett treatments. Caution, hope and next steps Research into cannabis for Rett is still early, and Leonard urges caution when interpreting results from small, open-label trials. 'I think that we need a larger national double-blind placebo-controlled study before making any judgement,' she said. 'I would hope that this would use an alternative outcome measure to the RSBQ.' Her research has shown that Rett's behavioural symptoms - like those measured by the RSBQ - tend to decrease with age; unlike its clinical severity, which often worsens. That disconnect, she believes, can muddy trial results, and partially explains why she urges a broader toolkit for measuring impact in future studies. Still, she acknowledged that apart from the Rett Syndrome Symptom Severity (RTT-SIS) scale, some of the other measures used in the NTI164 study 'were showing positive changes'. She's not easily swayed by early signals but she recognises momentum when it's building. And regulators seem to agree. A closer look under NTI's hood From a clinical standpoint, NTI164 is ticking key boxes. Its pharmacokinetic (PK) data shows rapid absorption, minimal THC exposure and consistent dosing with no cannabinoid build-up - making it suitable for chronic paediatric use. NTI164 has also shown promising results in other paediatric neurological conditions like autism and PANDAS/PANS, potentially supporting its use in Rett by building a broader safety and efficacy profile. Perhaps most notably, its primary cannabinoid, CBDA, doesn't just convert into CBD like many assume. It appears to act directly on the brain, interacting with receptors linked to mood and inflammation. That matters because Rett isn't just neurological, it's deeply inflammatory. 'The clear validation of systemic stability, safety and targeted therapeutic action highlights NTI164's potential as a disease-modifying therapy,' said Neurotech CEO, Dr Anthony Filippis. Whether that turns into a commercial home run is still to be seen, but NTI164 has already demonstrated solid safety and early signs of symptom relief. In Rett, that bar is high. So are expectations. And that's what makes Neurotech's path an interesting one to watch. At Stockhead we tell it like it is. While Neurotech is a Stockhead advertiser, it did not sponsor this article.

ABC News
7 hours ago
- ABC News
Australian scientists record accelerating glacier loss on sub-Antarctic Heard Island
Glaciers on the remote Australian territory of Heard Island have lost almost a quarter of their size in the past seven decades amid rising temperatures in the sub-Antarctic region, new research shows. The World Heritage-listed sub-Antarctic island, 4,100 kilometres south-west of Perth, is considered one of the most pristine places on the planet and a haven for wildlife. It's also home to the tallest mountain in Australia's external territories — a 2,745-metre-high active volcano called Big Ben, which is 517 metres taller than Mt Kosciuszko on the mainland. But scientists from Monash University's Securing Antarctica's Environmental Future (SAEF) research centre said glacier coverage on the island was undergoing accelerating decline. The research team used topographic maps and satellite imagery to identify changes to 29 glaciers on the island between 1947 and 2019. The study showed the loss of 64 square kilometres of glacier coverage over the 72-year period — a 22 per cent decline. The team said the rate of ice loss after 1988 was double that seen beforehand. The reduction in the island's glaciers occurred as temperatures in the area increased by 0.7 degrees Celcius. "While Heard Island is just about as remote as it's possible to be on Earth, it has still suffered profound consequences from climate warming, which is almost certainly due to rising greenhouse gas emissions in the 20th and 21st centuries," Dr Tielidze said. "The island's location in the Southern Ocean makes it a key part of the global climate system and an important indicator of the planet's health. The study has been published in the academic journal, The Chryosphere, ahead of a planned research voyage to Heard Island and nearby McDonald Island in late September. The RSV Nuyina will take almost two weeks to sail from Hobart to the remote islands, where science teams, including glaciologists, will conduct research for about 10 days. It will be the first Australian Antarctic Program voyage to the islands in almost 20 years, and will be followed up with a second voyage there in December. Professor Andrew Mackintosh, from Monash University, said the mission would allow researchers to better understand the impact of glacier retreat on the island's mountain biodiversity. "We'll explore two possible futures — one where strong action is taken to reduce greenhouse gas emissions, and another where little is done and emissions continue as usual," Professor Mackintosh said. "Although this mapping shows stark glacier retreat and further ice loss is unavoidable, whether we retain glaciers or lose most of them entirely is up to humans and the greenhouse gas emission pathway we follow.